siRNA-mediated inhibition of PCSK9 by RBD7022: a first-in-human trial to evaluate safety, pharmacokinetics (PK) and pharmacodynamic (PD) effects alone and when added to statin treatment.

Back

ESC2025 Premium Access

siRNA-mediated inhibition of PCSK9 by RBD7022: a first-in-human trial to evaluate safety, pharmacokinetics (PK) and pharmacodynamic (PD) effects alone and when added to statin treatment.

Session: New perspectives in cardiology (1) - Dyslipidaemias: current strategies and innovations

Topic: Lipid-Lowering Agents

Speaker: Associate Professor A. Gabrielsen (Gothenburg, SE)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Associate Professor Anders Gabrielsen

Ribocure Pharmaceuticals, Gothenburg (Sweden)

1 follower

13 more presentations in this session

Discussant - Dyslipidaemias: current strategies and innovations

Access

The benefits of intensive statin therapy in BIRISK patients with AMI: a multicenter cohort study

Speaker: Doctor M. Zheng (Tianjin, CN)

Atorvastatin versus rosuvastatin: a systematic review and meta-analysis of their effects on inflammatory biomarkers in randomized trials.

Speaker: Doctor I. Ullah (Peshawar, PK)

Access

Abstract

Efficacy of siRNA in lowering lipoprotein(a) and LDL-cholesterol: a meta-analysis of randomized controlled trials

Speaker: Ms L. Filagrana (Rio Do Sul, BR)

The efficacy and safety of low-intensity statins for high bleeding risk patients after PCI in Asian populations

Speaker: Doctor Z. Zhang (Tianjin, CN)

Access the full session

New perspectives in cardiology (1) - Dyslipidaemias: current strategies and innovations

Speakers: Associate Professor A. Gabrielsen, Doctor M. Zheng, Doctor I. Ullah, Ms L. Filagrana, Doctor Z. Zhang

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources